Free Trial
NASDAQ:AUPH

Aurinia Pharmaceuticals (AUPH) Stock Price, News & Analysis

Aurinia Pharmaceuticals logo
$12.14 +0.03 (+0.21%)
As of 11:26 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Aurinia Pharmaceuticals Stock (NASDAQ:AUPH)

Key Stats

Today's Range
$12.03
$12.18
50-Day Range
$7.47
$12.27
52-Week Range
$6.42
$12.53
Volume
202,703 shs
Average Volume
1.62 million shs
Market Capitalization
$1.60 billion
P/E Ratio
28.22
Dividend Yield
N/A
Price Target
$12.00
Consensus Rating
Buy

Company Overview

Aurinia Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
60th Percentile Overall Score

AUPH MarketRank™: 

Aurinia Pharmaceuticals scored higher than 60% of companies evaluated by MarketBeat, and ranked 392nd out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Aurinia Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Aurinia Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

  • Read more about Aurinia Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Aurinia Pharmaceuticals are expected to grow by 409.09% in the coming year, from $0.11 to $0.56 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Aurinia Pharmaceuticals is 28.16, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 28.65.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Aurinia Pharmaceuticals is 28.16, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 30.83.

  • Price to Book Value per Share Ratio

    Aurinia Pharmaceuticals has a P/B Ratio of 4.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Aurinia Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    7.88% of the float of Aurinia Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Aurinia Pharmaceuticals has a short interest ratio ("days to cover") of 4.7.
  • Change versus previous month

    Short interest in Aurinia Pharmaceuticals has recently decreased by 13.83%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Aurinia Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Aurinia Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.88% of the float of Aurinia Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Aurinia Pharmaceuticals has a short interest ratio ("days to cover") of 4.7.
  • Change versus previous month

    Short interest in Aurinia Pharmaceuticals has recently decreased by 13.83%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Aurinia Pharmaceuticals has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Aurinia Pharmaceuticals this week, compared to 4 articles on an average week.
  • Search Interest

    33 people have searched for AUPH on MarketBeat in the last 30 days. This is an increase of 32% compared to the previous 30 days.
  • MarketBeat Follows

    6 people have added Aurinia Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Aurinia Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $13,590,000.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    12.20% of the stock of Aurinia Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 36.83% of the stock of Aurinia Pharmaceuticals is held by institutions.

  • Read more about Aurinia Pharmaceuticals' insider trading history.
Receive AUPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aurinia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AUPH Stock News Headlines

Is This Stock the 'Next Nvidia'?
'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, and has now reached every AI company in America... including Nvidia, Microsoft, and Meta.tc pixel
See More Headlines

AUPH Stock Analysis - Frequently Asked Questions

Aurinia Pharmaceuticals' stock was trading at $8.98 on January 1st, 2025. Since then, AUPH stock has increased by 34.9% and is now trading at $12.11.

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) announced its earnings results on Thursday, July, 31st. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.17 by $0.01. The biotechnology company had revenue of $70.01 million for the quarter, compared to analysts' expectations of $64.27 million. Aurinia Pharmaceuticals had a net margin of 23.31% and a trailing twelve-month return on equity of 20.06%.
Read the conference call transcript
.

Aurinia Pharmaceuticals' top institutional shareholders include Armistice Capital LLC (1.24%), Geode Capital Management LLC (1.20%), Qube Research & Technologies Ltd (0.94%) and Arrowstreet Capital Limited Partnership (0.82%). Insiders that own company stock include Kevin Tang, Peter Greenleaf, Matthew Maxwell Donley, Joseph M Miller, Scott Michael Habig, Stephen P Robertson, Greg Keenan, David RW Jayne, Jeffrey Allen Bailey and Joseph P Hagan.
View institutional ownership trends
.

Shares of AUPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aurinia Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Intel (INTC).

Company Calendar

Last Earnings
7/31/2025
Today
8/28/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AUPH
CIK
1600620
Employees
300
Year Founded
N/A

Price Target and Rating

High Price Target
$17.00
Low Price Target
$9.00
Potential Upside/Downside
-0.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.43
Trailing P/E Ratio
28.16
Forward P/E Ratio
110.09
P/E Growth
N/A
Net Income
$5.75 million
Net Margins
23.31%
Pretax Margin
24.02%
Return on Equity
20.06%
Return on Assets
13.81%

Debt

Debt-to-Equity Ratio
0.18
Current Ratio
5.23
Quick Ratio
4.63

Sales & Book Value

Annual Sales
$260.11 million
Price / Sales
6.13
Cash Flow
$0.31 per share
Price / Cash Flow
39.59
Book Value
$2.55 per share
Price / Book
4.75

Miscellaneous

Outstanding Shares
131,630,000
Free Float
115,571,000
Market Cap
$1.59 billion
Optionable
Optionable
Beta
1.23

Social Links

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:AUPH) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners